$2.39
-0.08 (-3.24%)
Open$2.42
Previous Close$2.47
Day High$2.53
Day Low$2.33
52W High$13.93
52W Low$1.87
Volume—
Avg Volume316.9K
Market Cap5.11M
P/E Ratio—
EPS$-1.20
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,428.5% upside
Current
$2.39
$2.39
Target
$36.53
$36.53
$23.38
$36.53 avg
$47.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.73M | 3.10M | 899.1K |
| Net Income | -3,357,718 | -2,512,217 | -268,437 |
| Profit Margin | -90.1% | -85.6% | -29.9% |
| EBITDA | -3,550,379 | -2,803,940 | -429,552 |
| Free Cash Flow | — | — | -251,567 |
| Rev Growth | +20.3% | +20.3% | -1.1% |
| Debt/Equity | — | — | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.90 | +0.97% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $417.30 | +0.65% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.60 | +0.44% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $524.99 | -0.23% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.08 | -4.56% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.65 | -0.51% | 41.4 | 33.44B |